开云app官网登录入口网页版-官方正版

#施维雅#

5篇内容 | 1272人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2220366, encodeId=620522203660a, content=<a href='/topic/show?id=41651083831e' target=_blank style='color:#2F92EE;'>#Vorasidenib#</a>是由<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施维雅#</a>公司开发的<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>和IDH2突变酶的双重抑制剂，可通过口服给药，能够穿越血脑屏障，到达<a href='/topic/show?id=53668406668' target=_blank style='color:#2F92EE;'>#胶质瘤#</a>部位，大幅提高患者的生存!! <a href='/topic/show?id=b35011e938cd' target=_blank style='color:#2F92EE;'>#沃拉西尼#</a> , objectTitle=NEJM：20多年来胶质瘤治疗的首个重大突破，大幅延长患者生存期, objectType=article, longId=775467, objectId=fe17e7546715, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230606/1686014563030_5295905.jpg, objectUrl=/article/show_article.do?id=fe17e7546715, replyNumber=0, likeNumber=31, createdTime=2024-08-15, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=fe17e7546715, moduleTitle=NEJM：20多年来胶质瘤治疗的首个重大突破，大幅延长患者生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fe17e7546715)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1495678, encodeId=b8cc14956e8f1, content=<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施维雅#</a>, objectTitle=法国第二大制药公司施维雅（Servier）24亿美元收购Shire公司的肿瘤业务经营权, objectType=article, longId=147989, objectId=442014e9890d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442014e9890d, replyNumber=0, likeNumber=71, createdTime=2018-09-02, rootId=0, userName=chentianping, userId=b34a9182631, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442014e9890d, moduleTitle=法国第二大制药公司施维雅（Servier）24亿美元收购Shire公司的肿瘤业务经营权, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=442014e9890d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1495677, encodeId=b04814956e717, content=<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施维雅#</a>, objectTitle=美国FDA批准施维雅/辉瑞通用型CAR-T疗法进入临床试验, objectType=article, longId=92101, objectId=8c7e921016c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7e921016c, replyNumber=0, likeNumber=73, createdTime=2017-03-15, rootId=0, userName=chentianping, userId=b34a9182631, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7e921016c, moduleTitle=美国FDA批准施维雅/辉瑞通用型CAR-T疗法进入临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8c7e921016c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1495676, encodeId=725414956e667, content=<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施维雅#</a>, objectTitle=大冢及施维雅结直肠癌复方新药Lonsurf英国NICE批准, objectType=article, longId=75978, objectId=2011e597805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2011e597805, replyNumber=0, likeNumber=71, createdTime=2016-08-28, rootId=0, userName=chentianping, userId=b34a9182631, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2011e597805, moduleTitle=大冢及施维雅结直肠癌复方新药Lonsurf英国NICE批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2011e597805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1495675, encodeId=485214956e5d1, content=<a href='/topic/show?id=1ba85880eda' target=_blank style='color:#2F92EE;'>#施维雅#</a>, objectTitle=施维雅肾脏病青年研究与发展项目2014年项目申报通知, objectType=article, longId=33751, objectId=e64d33e51cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e64d33e51cc, replyNumber=0, likeNumber=74, createdTime=2014-04-25, rootId=0, userName=chentianping, userId=b34a9182631, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e64d33e51cc, moduleTitle=施维雅肾脏病青年研究与发展项目2014年项目申报通知, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e64d33e51cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

施维雅

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

#Vorasidenib#是由#施维雅#公司开发的#IDH1#和IDH2突变酶的双重抑制剂，可通过口服给药，能够穿越血脑屏障，到达#胶质瘤#部位，大幅提高患者的生存!! #沃拉西尼#

NEJM：20多年来胶质瘤治疗的首个重大突破，大幅延长患者生存期

2024-08-15发表于威斯康星

chentianping (审核中...)

前往app查看评论内容

#施维雅#

法国第二大制药公司施维雅（Servier）24亿美元收购Shire公司的肿瘤业务经营权

2018-09-02

chentianping (审核中...)

前往app查看评论内容

#施维雅#

美国FDA批准施维雅/辉瑞通用型CAR-T疗法进入临床试验

2017-03-15

chentianping (审核中...)

前往app查看评论内容

#施维雅#

大冢及施维雅结直肠癌复方新药Lonsurf英国NICE批准

2016-08-28

chentianping (审核中...)

前往app查看评论内容

#施维雅#

施维雅肾脏病青年研究与发展项目2014年项目申报通知

2014-04-25

科室
- - 订阅+
  - 更多科室
工具
服务